MARKET

BPTH

BPTH

Bio-Path Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.40
-0.06
-0.93%
After Hours: 6.47 +0.07 +1.09% 16:22 07/30 EDT
OPEN
6.47
PREV CLOSE
6.46
HIGH
6.70
LOW
6.40
VOLUME
27.54K
TURNOVER
--
52 WEEK HIGH
24.34
52 WEEK LOW
3.120
MARKET CAP
44.55M
P/E (TTM)
-2.6942
1D
5D
1M
3M
1Y
5Y
Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today
Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc.
Benzinga · 06/22 14:45
Thinking about buying stock in vTv Therapeutics, Score Media and Gaming, Bio-Path Holdings, Anavex Life Sciences, or Atossa Therapeutics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTVT, SCR, BPTH, AVXL, and ATOS.
PR Newswire - PRF · 06/22 12:30
Sanderson Farms, GameStop among notable premarket gainers
vTv Therapeutics (VTVT) +28% on licensing agreement with Cantex.Adial Pharmaceuticals (ADIL) +22%.Bio-Path Holdings (BPTH) +22% as USPTO grants a new patent.Beyond Air (XAIR) +12%.Sanderson Farms (SAFM) +12% as it explores a potential sale.Idera
Seekingalpha · 06/22 12:21
Bio-Path Gets New U.S. Patent Related to Drug Delivery Technology
marketwatch.com · 06/22 11:38
BRIEF-Bio-Path Granted Key Mechanism Of Action U.S. Patent For Bp1003
reuters.com · 06/22 11:20
Sector Update: Health Care
MT Newswires · 06/22 09:23
Bio-Path Cancer Treatment Program BP1003 Granted US Patent
MT Newswires · 06/22 08:03
Is Bio-Path Holdings, Inc. (BPTH) A Good Stock To Buy?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of March 31st. The ...
Insider Monkey · 06/15 19:22
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BPTH. Analyze the recent business situations of Bio-Path Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BPTH stock price target is 12.50 with a high estimate of 13.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 1.00M
% Owned: 14.39%
Shares Outstanding: 6.96M
TypeInstitutionsShares
Increased
5
89.66K
New
5
110.57K
Decreased
2
4.36K
Sold Out
4
63.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/President/Chief Executive Officer/Co-Founder/Chief Financial Officer/Treasurer/Director
Peter Nielsen
Secretary/Director/IR Contact Officer
Douglas Morris
Independent Director
Paul Aubert
Independent Director
Heath Cleaver
Independent Director
Martina Molsbergen
No Data
About BPTH
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. The Company's drug delivery and antisense technology, called DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a neutral charged lipid bilayer. In vivo, the DNAbilize delivered antisense drug substances are systemically distributed across the body to allow for reduction or elimination of proteins in blood diseases and solid organs. Using DNAbilize as a platform for drug manufacturing, the Company has approximately three antisense drug candidates in development to treat a total of over five different cancer disease indications.

Webull offers kinds of Bio-Path Holdings Inc stock information, including NASDAQ:BPTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BPTH stock methods without spending real money on the virtual paper trading platform.